Presentation is loading. Please wait.

Presentation is loading. Please wait.

STREAM (Evaluation of a Standardised Treatment Regimen of Anti-tuberculosis Drugs for Patients with Multidrug-resistant Tuberculosis) treatment regimens.

Published byΣπύρος Αλεξίου Modified over 6 years ago

Similar presentations

Presentation on theme: "STREAM (Evaluation of a Standardised Treatment Regimen of Anti-tuberculosis Drugs for Patients with Multidrug-resistant Tuberculosis) treatment regimens."— Presentation transcript:

1 STREAM (Evaluation of a Standardised Treatment Regimen of Anti-tuberculosis Drugs for Patients with Multidrug-resistant Tuberculosis) treatment regimens. STREAM (Evaluation of a Standardised Treatment Regimen of Anti-tuberculosis Drugs for Patients with Multidrug-resistant Tuberculosis) treatment regimens. WHO: World Health Organization; MDR-TB: multidrug-resistant tuberculosis; KM: kanamycin; INH: isoniazid; PTO: prothionamide; MFX: moxifloxacin; CFZ: clofazimine; EMB: ethambutol; PZA: pyrazinamide; BDQ: bedaquiline; LFX: levofloxacin. Riya Moodley, and Thomas R. Godec Eur Respir Rev 2016;25:29-35 ©2016 by European Respiratory Society

Download ppt "STREAM (Evaluation of a Standardised Treatment Regimen of Anti-tuberculosis Drugs for Patients with Multidrug-resistant Tuberculosis) treatment regimens."

Similar presentations

The TB Alliance-Bayer Moxifloxacin Deal

The TB Alliance-Bayer Moxifloxacin Deal
Management of Drug-Resistant Tuberculosis Your name Institution/organization Meeting Date International Standard 12.

Management of Drug-Resistant Tuberculosis Your name Institution/organization Meeting Date International Standard 12.
New approaches in TB diagnosis and treatment Prof. M.A. Tageldin.

New approaches in TB diagnosis and treatment Prof. M.A. Tageldin.
Second-line Anti-TB drugs

Second-line Anti-TB drugs
New drugs and regimens for TB: 2015 update

New drugs and regimens for TB: 2015 update
1 Constructing a regimen Session 5. USAID TB CARE II PROJECT Principles of designing an MDR-TB treatment regimen Include at least four second-line anti-TB.

1 Constructing a regimen Session 5. USAID TB CARE II PROJECT Principles of designing an MDR-TB treatment regimen Include at least four second-line anti-TB.
XDR-TB and management options Ninth Technical Advisory Group and National TB Programme Managers Meeting TB Control in the Western Pacific Region, Manila,

XDR-TB and management options Ninth Technical Advisory Group and National TB Programme Managers Meeting TB Control in the Western Pacific Region, Manila,
Module 3: Drug-Resistant TB. Learning Objectives Describe how drug resistance emerges Explain the difference between primary and secondary resistance.

Module 3: Drug-Resistant TB. Learning Objectives Describe how drug resistance emerges Explain the difference between primary and secondary resistance.
TB. Areas of Concern TB cases continue to be reported in every state Drug-resistant cases reported in almost every state Estimated 10-15 million persons.

TB. Areas of Concern TB cases continue to be reported in every state Drug-resistant cases reported in almost every state Estimated million persons.
Bedaquiline: Practical use and interim results in France Dr Mathilde Jachym 17 th of February 2015 - Yerevan New treatments and approaches.

Bedaquiline: Practical use and interim results in France Dr Mathilde Jachym 17 th of February Yerevan New treatments and approaches.
Christoph Lange & Giovanni Sotgiu Principles of designing a TB and MDR-TB drug regimen.

Christoph Lange & Giovanni Sotgiu Principles of designing a TB and MDR-TB drug regimen.
Elsevier Inc. items and derived items © 2010 by Saunders, an imprint of Elsevier Inc. Chapter 89 Antimycobacterial Agents: Drugs for Tuberculosis, Leprosy,

Elsevier Inc. items and derived items © 2010 by Saunders, an imprint of Elsevier Inc. Chapter 89 Antimycobacterial Agents: Drugs for Tuberculosis, Leprosy,
Introduction to the Forms Julie Tomaro, BSN Washington State Department of Health INTERJURISDICTIONAL TB NOTIFICATION (IJN) TRANSFER AND FOLLOW-UP FORMS.

Introduction to the Forms Julie Tomaro, BSN Washington State Department of Health INTERJURISDICTIONAL TB NOTIFICATION (IJN) TRANSFER AND FOLLOW-UP FORMS.
Anri Uys (MSc Pharmacology, BPharm NWU) Medicines Information Centre, Division of Clinical Pharmacology University of Cape Town.

Anri Uys (MSc Pharmacology, BPharm NWU) Medicines Information Centre, Division of Clinical Pharmacology University of Cape Town.
TB 101 Part II Brenda Mayes, R. N. March 2009. TREATMENT TB DISEASE MDR XDR LATENT TB INFECTION.

TB 101 Part II Brenda Mayes, R. N. March TREATMENT TB DISEASE MDR XDR LATENT TB INFECTION.
Treatment of Tuberculosis: New Case Case Studies Module 7A2 – March 2010.

Treatment of Tuberculosis: New Case Case Studies Module 7A2 – March 2010.
By Luke Carroll 1B.   Tuberculosis (TB) is an infectious disease that usually infects the lungs, but can attack almost any part of the body. What Is.

By Luke Carroll 1B.   Tuberculosis (TB) is an infectious disease that usually infects the lungs, but can attack almost any part of the body. What Is.
Infectious Conditions of the Lower Respiratory Tract.

Infectious Conditions of the Lower Respiratory Tract.
Acquired Drug Resistance  64 year old female of Hmong ethnicity with long standing, poorly controlled diabetes. No hx TB dx/tx.  11/6/08 CXR “active.

Acquired Drug Resistance  64 year old female of Hmong ethnicity with long standing, poorly controlled diabetes. No hx TB dx/tx.  11/6/08 CXR “active.
By: Mpho Kontle and Topo Moses. Introduction & Etiology Multi-drug-resistant tuberculosis (MDR-TB) is defined as tuberculosis that is resistant to at.

By: Mpho Kontle and Topo Moses. Introduction & Etiology Multi-drug-resistant tuberculosis (MDR-TB) is defined as tuberculosis that is resistant to at.

Similar presentations

Ads by Google